Results of Novel Mesothelioma Drug Presented at ASCO Meeting
A multicenter phase II clinical trial involving the latest orally administered protein inhibitor drug has shown considerable promise in helping control malignant mesothelioma.
The effectiveness of tazemetostat was presented last week at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
The trial study, which will conclude late 2018, involves 74 previously treated patients with recurring mesothelioma.
“We’ve seen benefit for some patients with this treatment and patients who have benefited over a long period of time,” medical oncologist Dr. Marianna Koczywas, City of Hope Cancer Treatment &am...
Source: Asbestos and Mesothelioma News - June 14, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news
‘Right to Try Act’ Could Aid Mesothelioma Patients
Patients with mesothelioma may soon find an easier path to experimental drugs and treatments after President Donald Trump signed the “Right to Try Act” into law last week.
The new legislation will give terminally ill patients a more direct and quicker line to drugs still awaiting approval from the U.S. Food and Drug Administration (FDA), bypassing the often-cumbersome application process.
The law also will protect doctors and pharmaceutical companies from the legal risks of allowing unapproved treatments.
The bill was passed by the Senate in August 2017 and cleared the House of Representatives late last month.
“I do...
Source: Asbestos and Mesothelioma News - June 6, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news
FDA Expands Lilly's ALIMTA(R) (pemetrexed) Label to Include Combination with KEYTRUDA(R) (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression
New approval based on KEYNOTE-021, Cohort G1, results
INDIANAPOLIS, June 5, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a ... Biopharmaceuticals, Oncology, FDA Eli Lilly, ALIMTA, pemetrexed, KEYTRUDA, NSCLC (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 5, 2018 Category: Pharmaceuticals Source Type: news
Pembrolizumab, Pemetrexed, and Carboplatin Improve Lung Cancer Survival
Bryant FurlowJun 3, 2018Adding pembrolizumab to pemetrexed and carboplatin for advanced nonsquamous NSCLC is associated with improved overall survival at 24 months. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2018 Category: Cancer & Oncology Authors: A Source Type: news
Could Mesothelioma Chemotherapy Ever Be Obsolete?
Oncologist Dr. Arek Dudek at Regions Hospital Cancer Care Center in St. Paul, Minnesota, believes his clinical trial involving a novel immunotherapy combination could change the way doctors treat pleural mesothelioma.
Dudek is opening the only Phase II trial evaluating the combination of nivalumab (Opdivo) and ramucirumab (Cyramza) for previously treated mesothelioma patients.
“This strategy – if successful, like we think it will be – could make treatment with chemotherapy obsolete,” Dudek told Asbestos.com. “People can be really excited about this one.”
He based his optimism on the potential synergy between th...
Source: Asbestos and Mesothelioma News - June 1, 2018 Category: Environmental Health Authors: Walter Pacheco Source Type: news
Novel Mesothelioma Treatment Uses Electrical Fields
Oncologists in 2019 may begin offering patients with pleural mesothelioma a novel, tumor-fighting tool involving electric currents that enhance standard-of-care treatment and extend survival, according to the device manufacturer.
Tumor Treating Fields (TTF) is the name of the new technology. It is designed to disrupt cancer cell division through electric fields tuned to specific frequencies.
In an ongoing multicenter phase II clinical trial in Europe, TTF has shown an ability in first-line treatment to improve the effectiveness of standard chemotherapy for mesothelioma patients.
The trial success has led the manufacturer t...
Source: Asbestos and Mesothelioma News - May 24, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news
ONCOS-102 Mesothelioma Trial Moves Forward
Oncologists in Spain are recruiting patients for the randomized phase of the pleural mesothelioma clinical trial involving ONCOS-102, the promising immunotherapy vaccine.
Optimism surrounding the trial stems from encouraging results obtained recently in the six-patient safety cohort used as a precautionary lead-in.
The trial involves the vaccine in combination with standard-of-care chemotherapy for patients with inoperable disease.
ONCOS-102 is a scientifically engineered adenovirus that is designed to activate a patient’s immune system to selectively target cancer cells.
It is being developed by Targovax, a Scandinavian...
Source: Asbestos and Mesothelioma News - May 17, 2018 Category: Environmental Health Authors: Daniel King Source Type: news
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
This research article has led to a Practice Update in DynaMed Plus. It concludes that addition of pembrolizumab to chemotherapy with pemetrexed and platinum-based drug increases overall survival in patients with previously untreated metastatic nonsquamous non-small cell lung cancer. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 9, 2018 Category: Consumer Health News Source Type: news
New Clinical Trial Focuses on Immunotoxins and Mesothelioma
An exciting new mesothelioma clinical trial will study one approach for improving how well immunotoxin drugs work.
The phase I trial is enrolling peritoneal and pleural mesothelioma patients.
Immunotoxins, which are targeted therapies, attach to and destroy cancer cells. This approach already has shown promise in a small clinical trial.
This new clinical trial will give mesothelioma patients an immunotoxin in combination with another substance to suppress the immune system.
The goal of the National Cancer Institute (NCI) clinical trial is to learn how safe and tolerable the combination of the immunotoxin and immune suppre...
Source: Asbestos and Mesothelioma News - February 26, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news
Only U.S. Cryotherapy Trial for Mesothelioma Finds Success
Thoracic surgeon Dr. Shanda Blackmon at the Mayo Clinic in Rochester, Minnesota, believes there is a place for cryotherapy in the future multidisciplinary treatment of pleural mesothelioma.
She wants to show it with this groundbreaking clinical trial.
“We think [cryotherapy] could play an important role in treatment,” Blackmon told Asbestos.com. “So far, things look promising, but you can’t say anything specific without more numbers. Right now, it’s a little like telling a story.”
Cryotherapy involves destroying cancer cells, or any abnormal tissues, by freezing them with controlled nitrogen vapors. It is often...
Source: Asbestos and Mesothelioma News - February 14, 2018 Category: Environmental Health Authors: Daniel King Tags: ADI-PEG 20 cryoablation cryotherapy intrapleural measles virus Mayo Clinic mesothelioma clinical trial Opdivo pacific mesothelioma center pleural mesothelioma pleuroscopy Shanda Blackmon Surgery for Mesothelioma After Radiation Thera Source Type: news
Study: Preoperative Chemotherapy Useful for Mesothelioma
Oncologists in France are exploring the use of bidirectional chemotherapy as a pre-operative tool for peritoneal mesothelioma, increasing the eligibility of patients for aggressive surgery.
Their bidirectional chemotherapy — which typically includes a pemetrexed (Alimta) and cisplatin combination — is delivered directly into the abdominal cavity to reduce tumor burden and make cytoreductive surgery more manageable.
Doctors at Gustave Roussy, one of Europe’s premier cancer centers, documented this novel use in a study published in the November issue of Annals of Surgical Oncology.
“This is the first study to demonst...
Source: Asbestos and Mesothelioma News - December 13, 2017 Category: Environmental Health Authors: Daniel King Tags: bidirectional chemotherapy cytoreductive surgery Gustave Roussy hyperthermic intraperitoneal chemotherapy Paul Sugarbaker peritoneal mesothelioma Washington Cancer Institute Source Type: news
French Oncologists Upgrade Mesothelioma Standard of Care
Oncologists throughout France have joined the U.S.-based National Comprehensive Cancer Network (NCCN) in upgrading their recommended standard-of-care treatment regimen for unresectable pleural mesothelioma.
Both groups have added bevacizumab (Avastin) to the traditional cisplatin and pemetrexed chemotherapy combination, expecting to see longer patient survival.
“This is a major advancement for the care of mesothelioma patients,” Dr. Gerard Zalcman, head of thoracic oncology at Bichat-Claude Bernard Hospital, told Asbestos.com. “Clearly, this drug can change the natural history of this tumor.”
Bevacizumab is known a...
Source: Asbestos and Mesothelioma News - November 20, 2017 Category: Environmental Health Authors: Daniel King Tags: American Society of Clinical Oncology Avastin bevacizumab Bichat-Claude Bernard Hospital French Cooperative Thoracic Intergroup Gerard Zalcman National Comprehensive Cancer Network nintedanib Ofev pleural mesothelioma chemotherapy Source Type: news
Eagle Pharma Gets Tentative FDA Approval for Lilly's Alimta Version Eagle Pharma Gets Tentative FDA Approval for Lilly's Alimta Version
Eagle Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration tentatively approved its diluted version of Eli Lilly and Co ' s blockbuster cancer drug Alimta.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 30, 2017 Category: Consumer Health News Tags: Pharmacist News Source Type: news
Eagle Pharma gets tentative FDA approval for Lilly's Alimta version
(Reuters) - Eagle Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration tentatively approved its diluted version of Eli Lilly and Co's blockbuster cancer drug Alimta. (Source: Reuters: Health)
Source: Reuters: Health - October 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
